Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Major Histocompatibility Complex class II (MHC II) antigen presentation machinery is a multi-protein system essential for the adaptive immune system's ability to recognize foreign pathogens. This machinery functions primarily in professional antigen-presenting cells, such as dendritic cells, B cells, and macrophages, where it processes exogenous proteins into immunogenic peptides within endosomal and lysosomal compartments (PMID: 30104468). Key components include the MHC II heterodimers (HLA-DR, HLA-DQ, HLA-DP), the invariant chain (CD74) which chaperones the MHC II complex, and the specialized chaperone HLA-DM, which facilitates the loading of high-affinity peptides (UniProt: P01903, P04233). Once loaded, the MHC II-peptide complex is transported to the cell surface to activate CD4+ T helper cells, triggering a coordinated immune response (StatPearls: MHC Class II). Dysregulation of this pathway is a hallmark of many autoimmune diseases, such as rheumatoid arthritis, where self-peptides are inappropriately presented, while many tumors downregulate this machinery to evade immune detection (PMID: 31435310). Pharmacological intervention often involves drugs like hydroxychloroquine, which raises endosomal pH to inhibit the cathepsins required for antigen processing, thereby dampening the autoimmune response (PubMed: 25135138).
Modulation of endosomal pH to inhibit antigen proteolysis by cathepsins and interference with the HLA-DM-mediated exchange of CLIP for antigenic peptides on MHC class II molecules.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Major Histocompatibility Complex class II (MHC II) antigen presentation machinery (MHC II machinery).